Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer

British Journal of Cancer

Volumn 94, Issue 11, 2006, Pages 1604-1609

  Ciardiello, F ^a   Troiani, T ^a   Caputo, F ^b   De Laurentiis, M ^b   Tortora, G ^b   Palmieri, G ^b   De Vita, F ^a   Diadema, M R ^a   Orditura, M ^a   Colantuoni, G ^c   Gridelli, C ^c   Catalano, G ^a   De Placido, S ^b   Bianco, A R ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c S G MOSCATI HOSPITAL   (Italy)

Author keywords

Combination therapy; Metastatic breast cancer; Small molecule EGFR tyrosine kinase inhibitors; Taxanes

Indexed keywords

AMINOTRANSFERASE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACNE; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FEVER; HUMAN; HYPERSENSITIVITY; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; QUINAZOLINES; RECEPTORS, ESTROGEN; TAXOIDS; TREATMENT OUTCOME;

EID: 33745277110     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603141     Document Type: Article

References (44)

1. Albain K, Elledge R, Gradishar W (2002) Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Res Treat 76(Suppl. 1): S33 (abstr.)
2. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis S, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737-744
3. Baselga J, Albanell J, Ruiz A, Lluch A, Gascón P, Guillém V, González S, Sauleda S, Marimón I, Tabernero JM, Koehler MT, Rojo F (2005) Phase II antitumour and pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 23: 5323-5333
4. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F (1995) Docetaxel (Taxotere®): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 6: 339-368
5. Bonneterre J, Roche H, Monnier A, Guastalla JP, Namer M, Fargeot P, Assadourian S (2002) Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 87: 1210-1215
6. Burris III HA (2001) Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol 28: 38-44
7. Ciardiello F, Caputo R, Bianco R, Damiano V, Somatico G, De Placido S, Bianco AR, Tortora G (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6: 2053-2063
8. Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G, Bianco AR, Tortora G (2002) ZD1839 ('Iressa'), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer 98: 463-469
9. Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7: 2958-2970
10. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800-1808
11. Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143-151
12. Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL (1994) The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 29: 41-49
13. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 2197-2205
14. Grunwald V, Hidalgo M (2003) Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Nat Cancer Inst 95: 851-867
15. Herbst RS, Fukuoka M, Baselga J (2004) Gefitinib, a novel targeted approach to treating cancer. Nat Rev Cancer 4: 956-965
16. Hortobagyi GN (2002) Can we cure limited metastatic breast cancer? J Clin Oncol 20: 620-623
17. Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, Chang A, Lee DC (1999) Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 126: 2739-2750
18. Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Amer Statist Assoc 53: 457-481
19. Klijn JG, Berns PM, Schmitz PI, Foekens JA (1992) The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13: 3-17
20. Klijn JG, Look MP, Portengen H (1994) The prognostic value of epidermal growth factor receptor (EGFR) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res Treat 29: 73-83
21. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JMW, Harper ME, Barrow D, Wakeling AE, Nicholson RI (2003) Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144: 1032-1044
22. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauric L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Llunch A, Kennedy J, O' Byrne K, Conte P, Grenn M, Ward C, Mayene K, Extra JM (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265-4274
23. Matsui Y, Halter SA, Holt JT, Hogan BL, Coffey RJ (1990) Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell 61: 1147-1155
24. Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787-2799
25. Mincey BA, Perez EA (2004) Concise review for clinicians: advances in screening, diagnosis and treatment of breast cancer. Mayo Clin Proc 79: 810-816
26. Montemurro F, Choa G, Faggiuolo R, Donadio M, Minischetti M, Durando A, Capaldi A, Vietti-Ramus G, Alabiso O, Aglietta M (2004) A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Oncology 66: 38-45
27. Montero A, Fossella F, Hortobagyi G, Valero V (2005) Docetaxel for treatment of solid tumors: a systematic review of clinical data. Lancet Oncol 6: 229-239
28. Nabholtz JM, Gligorov J (2005) Docetaxel in the treatment of breast cancer: current experience and future prospectives. Expert Rev Anticancer Ther 5: 613-633
29. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline- containing chemotherapy. J Clin Oncol 17: 1413-1424
30. Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM (2002) Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Ann N Y Acad Sci 963: 104-115
31. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-2823
32. Polychronis A, Sinnett HD, Hadjiminas D, Singhal H, Mansi J, Shivapatham D, Shousha S, Jiang J, Peston D, Barrett N (2005) Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal breast cancer patients with oestrogen receptor-positive and epidermal growth factor receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol 6: 383-391
33. Ringel I, Horwitz SB (1991) Studies with RP 56976 (Taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288-291
34. Robertson JF, Gutteridge E, Cheung KL, Owers R, Koehler M, Hamilton L, Gee J, Nicholson RI (2003) Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: Results from a phase II study. Prom Am Soc Clin Oncol 22, (abstr. 23)
35. Riou JF, Naudin A, Lavelle F (1992) Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 187: 164-170
36. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol-Hematol 19: 183-232
37. Sandgren EP, Luetteke NC, Qiu TH, Palmiter RD, Brinster RL, Lee DC (1990) Overexpression of TGF alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61: 1121-1135
38. Shou J, Masserweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96: 926-935
39. Sirotnak FM, Zakowsky MF, Miller VA, Scher HI, Kris MG (2000) Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6: 4885-4892
40. Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lönn S, Bengtsson N-O, stenstad B, Mjaaland I, Palm-Sjövall M, Wist E, Valvere V, Anderson H, Bergh J (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35: 1194-1201
41. Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Antón A, Laurent C, Mayordomo JI, Estaun N, Losa I, Guillem V, Garcia-Conde J, Tisaire JL, Baselga J (2004) A multicenter randomized phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15: 1358-1365
42. Tedesco KL, Thor AD, Johnson DH, Shyr Y, Blum KA, Goldstein LJ, Gradishar WJ, Nicholson BP, Merkel DE, Murrey D, Edgerton S, Sledge Jr GW (2004) Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 22: 1071-1077
43. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors :European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
44. von Minckwitz G, Jonat W, Fasching P, du Bois A, Kleeberg U, Lück HJ, Kettner J, Hilfrich J, Eiermann W, Torode J, Schneeweiss A (2005) A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 89: 165-172